Drugs / ES-481
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05234762 | Nov 2021 → Dec 2023 | essential tremor | ES Therapeutics Australia Pty Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT04737174 | Mar → Oct 2021 | epilepsy | ES Therapeutics Australia Pty Ltd | Withdrawn | No outcome recorded |
| Phase 2 | NCT04714996 | Oct 2020 → Dec 2023 | epilepsy | ES Therapeutics Australia Pty Ltd | Unknown | Mixed |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ES-481 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04737174 ↗ |
| Action | Inhibit | “novel potent and selective antagonist of TARP-y8-dependent AMPA receptors” PMID 42312676 ↗ Jun 2026 |
| Route | Oral | “Administered as 25 mg oral gelatin capsules” NCT04737174 ↗ |